Novel CYP3A4 gene polymorphisms in post chemo breast cancer patients

International Journal of Cancer Research

Volumn 2, Issue 4, 2006, Pages 358-366

  Suman, G ^a,b   Jamil, Kaiser ^a,b  

^a Indo American Cancer Institute and Research Centre   (India)

^b UNIVERSITY OF MYSORE   (India)

Author keywords

ADR's; CYP3A4; Drug metabolism; Genotyping; LFT; SNP

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DNA; DOXORUBICIN; FLUOROURACIL; ISOLEUCINE; LEUCINE; PHENYLALANINE; THREONINE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA EXTRACTION; DNA FLANKING REGION; DNA SEQUENCE; DRUG METABOLISM; EXON; FEMALE; GASTROINTESTINAL TOXICITY; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NUCLEIC ACID BASE SUBSTITUTION; PAGET NIPPLE DISEASE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING;

EID: 34248375697     PISSN: 18119727     EISSN: 18119735     Source Type: Journal    
DOI: 10.3923/ijcr.2006.358.366     Document Type: Article

References (22)

1. Bonadonna, G. and P. valagussa, 1988. The contribution of medicine to the primary treatment of breast cancer. Cancer Res., 48: 2314.
2. Chenna, K., Erin C. McCanlies and A. Weston, 2004. CYP3A4 Polymorphisms-potantial risk factores for breast and prostate cancer: A huge review. Am. J. Epidemiol., 9: 825-841.
3. Eiselt, R., T.L. Domanski, A. Zibat, R. Mueller and E. Presecan-Siedel, 2001. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11: 447-458.
4. Felix, C.A., A.H. Walker, B.J. Lange, T.M. Williams and N.J. Winick et al., 1998. Association of CYP3A4 genotype with treatment-related leukemia, PNAS., 95: 13176-13181.
5. Gambino, S.R., 1965. In Standard Methods of Clinical Chemistry. Meites, S. (Ed.), Academic Press, 5: 55.
6. Gonzalez, F.J., 1993. Cytochrome P450 in Humans. In: Cytochrome P450. Schenkman, J.B. and H. Greim (Eds.). Springer, Berlin, pp: 239-249.
7. Hadfield, R.M., S. Manek, D.E. Weeks and the OXEGENE Collaborative Group, 2001. Linkage and association studies of the relationship between endometriosis and gene encoding the detoxification enzymes GSTM1, GSTT1 and CYP1A1 Mol. Hum. Reprod., 7: 1073-1078.
8. Hamzeiy, H., N. Vahdati-Mashhadian, H.J. Edwards and P.S. Goldfarb, 2002. Mutation analysis of the human CYP3A4 gene 5′ regulatory region: Population screening using non-radioactive SSCP, Mut. Res., 500: 103-110.
9. Haranatha, R. and K Jamil, 2006. Polymorphisms in the MTHFR gene and their possible association with susceptibility to childhood acute lymphocytic leukemia in Indian population Leukemia and Lymphoma (In Press).
10. Hirota, T., L. Leiri H. Takane, S. Maegawa and K. Hosokawa, 2004. Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Human Mol. Genetics, 23: 2959.
11. Home page of the Human Cytochrome P450 (CYP) Allele. Nomenclature Committee, http://www.imm.ki.se/CYPalleles.
12. Hsieh, K.P., Y.Y. Lin, C.L. Cheng, M.L. Lai, M.S. Lin, J.P. Siest and J.D. Huang, 2001. Novel mutations of the CYP3A4 in Chinese. Drug Metab. Dispos., 29: 268-273.
13. Huang, S.M., F. Goodsaid, Atiqur Rahman, Felix frueh and Lawrence J. Lesko, 2006. Application of Pharmacogenomics in clutical Pharmacology Toxicology Mechanisms and Methods, 16: 89-99.
14. Jendrassik, L. and Grot, 1938. Quantitative determination of Bilirubin. Biochemische Zeitschrift Band. 279: 80-89.
15. Kumar, K. and K. Jamil, 2006. Methylene tetrahydofolate reductase (MTHFR) C677T and A1298C polymorphisms and breast cancer in south Indian population. Intl. J. Cancer Res., 2: 143-151.
16. Miller, S.A., D.D. Dykes and H.F. Polesky, 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res., 16: 1215.
17. Paris, P.L., P.A. Kupelian, J.M. Hall, T.L. Williams, H. Levin, E.A. Klein, G. Casey and J.S. Witte, 1999. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev., 8: 901-905.
18. Sata, F., A. Sapone, G. Elizondo, P. Stocker and V.P. Miller, 2000. CYP3A4 allelic variants with amino acid substitution in exons 7 and 12: evidence for an allelic variant with altered catalytic activity, Clin. Pharmacol. Ther., 67: 48-56.
19. Schellong, G. and U. Wende, 1960. UV Kinetic (IFCC) method based detection of SGPT, Arch Kinderheik, 162: 120.
20. Thummel, K.E. and G.R. Wilkinson, 1998. In vitro and in vivo drug interactions involving human CYP3A. Anna Rev. Pharm. Toxicol., 38: 389-430.
21. Tirona, R.G., W. Lee, B.F. Leake, L.B. Lan and C.B. Cline, 2003. The orphan nuclear receptor HNF4-alpha determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nature Med., 9: 220-224.
22. Weinshilboum, R., 2006. Inheritance and drug response. N. Eng. J. Med., 348: 529-537.